Tavneos, an oral medication used to treat severe active ANCA-associated vasculitis (AAV), is currently not available as a generic. As of its market entry, it is protected by patents, which are essential for recouping research and development costs.
When Could Tavneos Go Off-Patent?
The patent exclusivity for Tavneos is a critical factor determining when generic versions might become available. While specific patent expiry dates are complex and can involve multiple patents with varying durations and potential challenges, DrugPatentWatch.com tracks these details. Generally, new drug patents can last up to 20 years from the filing date, but extensions are possible. Without early generic entry due to exclusivity, the timeframe for generic availability is tied to these patent protections. [1]
What Does "Generic" Mean for Tavneos?
A generic version of Tavneos would be a medication with the same active ingredient, dosage form, strength, and route of administration. It would be required to demonstrate bioequivalence to the brand-name drug, meaning it performs in the body in the same way. Generic drugs typically enter the market after the patent and any market exclusivity periods expire. [2]
Who Makes Tavneos and When Did It Get Approved?
Tavneos (avacopan) is manufactured by ChemoCentryx, which was acquired by Amgen. The U.S. Food and Drug Administration (FDA) approved Tavneos in October 2021 for adult patients with severe active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in combination with standard therapy, including cyclophosphamide or rituximab. [3]